Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in Primary Breast Cancer

Japanese Journal of Clinical Oncology

Volumn 38, Issue 4, 2008, Pages 250-258

  Ueda, Shigeto ^a   Tsuda, Hitoshi ^a   Asakawa, Hideki ^a   Shigekawa, Takashi ^b   Fukatsu, Kazuhiko ^a   Kondo, Nobuo ^a   Yamamoto, Mikio ^a   Hama, Yukihiro ^c   Tamura, Katsumi ^c   Ishida, Jiro ^c   Abe, Yoshiyuki ^c   Mochizuki, Hidetaka ^a  

^a NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

^b SAITAMA MEDICAL UNIVERSITY   (Japan)

^c Tokorozawa PET Diagnostic Imaging Clinic   (Japan)

Author keywords

18F FDG; Breast cancer; PET CT; Prognosis; SUV

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INVASION; CANCER MORTALITY; CANCER RELAPSE; CANCER SIZE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CORRELATION ANALYSIS; DRUG UPTAKE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; MITOSIS; MULTIVARIATE ANALYSIS; PAGET NIPPLE DISEASE; PREDICTION; PREOPERATIVE PERIOD; PROGNOSIS; SCORING SYSTEM; SIMULATION;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, LOBULAR; CONTRAST MEDIA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RADIOPHARMACEUTICALS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TOMOGRAPHY, X-RAY COMPUTED; TUMOR MARKERS, BIOLOGICAL;

EID: 42549089353     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyn019     Document Type: Article

References (20)

1. Vansteenkiste JF, Stroobants SG, Dupont PJ, De Leyn PR, Verbeken EK, Deneffe GL, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999;17(10):3201-6.
2. Santiago JF, Gonen M, Yeung H, Macapinlac H, Larson S. A retrospective analysis of the impact of 18F-FDG PET scans on clinical management of 133 breast cancer patients. Q J Nucl Med Mol Imaging 2006;50(1):61-7.
3. Port ER, Yeung H, Gonen M, Liberman L, Caravelli J, Borgen P, et al. 18F-2-fluoro-2-deoxy-D-glucose positron emission tomography scanning affects surgical management in selected patients with high-risk, operable breast carcinoma. Ann Surg Oncol 2006;13(5):677-84.
4. Juweid ME, Cheson BD. Positron-emission tomography and assessment of cancer therapy. N Engl J Med 2006;354(5):496-507.
5. Buck AK, Schirrmeister H, Mattfeldt T, Reske SN. Biological characterisation of breast cancer by means of PET. Eur J Nucl Med Mol Imaging 2004;31(Suppl 1):S80-7.
6. Buck A, Schirrmeister H, Kuhn T, Shen C, Kalker T, Kotzerke J, et al. FDG uptake in breast cancer: Correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging 2002;29(10): 1317-23.
7. Smith TA, Sharma RI, Thompson AM, Paulin FE. Tumor 18F-FDG incorporation is enhanced by attenuation of P53 function in breast cancer cells in vitro. J Nucl Med 2006;47(9):1525-30.
8. Tatsumi M, Cohade C, Mourtzikos KA, Fishman EK, Wahl RL. Initial experience with FDG-PET/CT in the evaluation of breast cancer. Eur J Nucl Med Mol Imaging 2006;33(3):254-62.
9. Sato K, Tamaki K, Shigekawa T, Tsuda H, Kosuda S, Kusano S, et al. Clinically useful detection criteria for sentinel nodes in patients with breast cancer using a radioisotope technique. Jpn J Clin Oncol 2002;32(10):403-6.
10. Tsuda H, Tani Y, Weisenberger J, Kitada S, Hasegawa T, Murata T, et al. Frequent KIT and epidermal growth factor receptor overexpressions in undifferentiated-type breast carcinomas with 'stem-cell-like' features. Cancer Sci 2005;96(6):333-9.
11. Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: Experience from a large study with long-term follow-up. Histopathology 1991;19:403-10; Histopathology 2002;41(3A):151.
12. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19(4):980-91.
13. Bos R, van Der Hoeven JJ, van Der Wall E, van Der Groep P, van Diest PJ, Comans EF, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol 2002;20(2):379-87.
14. Crippa F, Seregni E, Agresti R, Chiesa C, Pascali C, Bogni A, et al. Association between [18F]fluorodeoxyglucose uptake and postoperative histopathology, hormone receptor status, thymidine labelling index and p53 in primary breast cancer: A preliminary observation. Eur J Nucl Med 1998;25(10):1429-34.
15. Oshida M, Uno K, Suzuki M, Nagashima T, Hashimoto H, Yagata H, et al. Predicting the prognoses of breast carcinoma patients with positron emission tomography using 2-deoxy-2-fluoro[18F]-D-glucose. Cancer 1998;82(11):2227-34.
16. Higashi K, Ueda Y, Arisaka Y, Sakuma T, Nambu Y, Oguchi M, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002;43(1):39-45.
17. Ohtsuka T, Nomori H, Watanabe K, Kaji M, Naruke T, Suemasu K, et al. Prognostic significance of [(18)F]fluorodeoxyglucose uptake on positron emission tomography in patients with pathologic stage I lung adenocarcinoma. Cancer 2006;107(10):2468-73.
18. Guo J, Higashi K, Ueda Y, Oguchi M, Takegami T, Toga H, et al. Microvessel density: Correlation with 18F-FDG uptake and prognostic impact in lung adenocarcinomas. J Nucl Med 2006;47(3):419-25.
19. Chen YK, Su CT, Ding HJ, Chi KH, Liang JA, Shen YY, et al. Clinical usefulness of fused PET/CT compared with PET alone or CT alone in nasopharyngeal carcinoma patients. Anticancer Res 2006;26(2B): 1471-7.
20. Antoch G, Saoudi N, Kuehl H, Dahmen G, Mueller SP, Beyer T, et al. Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET. J Clin Oncol 2004;22(21):4357-68.